Hiperplasia prostática benigna (HPB), sintomas do trato urinário inferior (LUTS) e função sexual / Benign Prostatic Hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS), and Sexual Function

A hiperplasia prostática benigna (HPB) representa o crescimento não maligno do tecido da próstata. Proliferação de células estromais e epiteliais na zona de transição da próstata causa compressão uretral e obstrução do fluxo vesical. Isso pode levar a manifestações de LUTS (lower urinary tract symptoms): urgência urinária, noctúria, dificuldades de micção, esvaziamento incompleto da bexiga, menor força e/ ou interrupção do jato e inflamações. Mecanismos do LUTS/HPB compartilhados afetam a função sexual masculina. Atividade aumentada de subtipos de receptores α1-adrenérgicos na próstata está associada à HPB. Tais receptores, também presentes no pênis, podem inibir a ereção, devido à HPB. Quanto à correlação entre LUTS e disfunção sexual, aventa-se que ambas resultem da contração anômala da musculatura lisa, por ativação dos receptores α1-adrenérgicos. LUTS/HPB causam desconforto nos homens, devido à obstrução urinária, ejaculação dolorosa, disfunção erétil (DE), distúrbios ejaculatórios e baixa libido, que prejudicam a qualidade de vida, deles e de suas parcerias. A noctúria interfere negativamente na qualidade do sono e na disposição para a atividade sexual. Tratamentos para LUTS/HPB podem induzir disfunções sexuais. Entre eles, ressecção transuretral (RTU), α1-bloqueadores, inibidores da 5α-redutase e terapia combinada (α1-bloqueador e 5α-redutase). Os efeitos prejudiciais do LUTS/HPB e de seu tratamento sobre a função sexual ainda são subdiagnosticados e insuficientemente tratados. A atividade sexual deve ser investigada antes e durante o tratamento, também orientando o paciente sobre os possíveis efeitos de cada opção terapêutica sobre a função sexual, evitando-se assim o abandono do tratamento.

Association between interleukin-6 and lower urinary tract symptoms of benign prostatic hyperplasia / Relación entre la interleucina-6 y los síntomas urinarios de la hiperplasia prostática benigna

Objective: To evaluate the association between IL-6 in prostatic tissue/blood sample and BPH-LUTS, so as to preliminarily discover an indicator of inflammation that could show the severity of LUTS. Patients and methods: The prostatic tissues and blood samples were collected from 56 patients who underwent transurethral plasmakinetic resection of the prostate (TUPKRP). The association between IL-6 detected on prostatic tissues/blood sample and LUTS parameters, including international prostate symptom score (IPSS), peak flow rate (Qmax) and urodynamic parameters were analyzed with SPSS version 18.0, and p-value <0.05 was chosen as the criterion for statistical significance. Results: The TPSA and prostate volume (PV) were found to be higher in the inflammation group (p=0.021, 0.036). There was a positive association between prostate tissue inflammation and LUTS ([IPSS, storage symptoms score (SSS), voiding symptoms score (VSS), p<0.05], [Qmax, p=0.025], [obstruction, p=0.027] and [AUR, p=0.018]). The level of serum IL-6 was significantly higher in inflammatory group (p=0.008). However, no differences were observed in different degrees of inflammation (p=0.393). The level of IL-6 in prostatic tissue significantly increased with the degree of inflammation (p<0.001), and the intensity of IL-6 expression was statistically correlative with the degree of inflammation (p<0.001). The IL-6 expression in prostatic tissue was statistically relevant with IPSS (p=0.018) and SSS (p=0.012). Conclusion: IL-6 expression in prostatic tissue is associated with storage IPSS, suggesting chronic inflammation might contribute to storage LUTS. (AU)

Objetivo: Evaluar la relación entre il-6 y bph-lut en muestras de tejido prostático/sangre, con el fin de identificar indicadores de inflamación que reflejen la gravedad de los lut. Pacientes y métodos: Se recolectaron muestras de tejido prostático y sangre de 56 pacientes sometidos a una plasmatectomía transuretral prostática. Se aplicó la versión 18.0 de SPSS para analizar la correlación entre el il-6 de tejido prostático/muestra de sangre y los parámetros relacionados con los LUTS (puntuación internacional de síntomas prostáticos (IPSS), flujo máximo (Qmax), parámetros urodinámicos), con UN valor p<0,05 como criterio para una diferencia estadísticamente significativa. Resultados: Hubo diferencias estadísticamente significativas (p=0,021, 0,036) entre el grupo con inflamación y el grupo sin inflamación en TPSA y PV. La inflamación del tejido prostático se relacionó positivamente con LUTS ([IPSS, puntuación de síntomas de almacenamiento (SSS), puntuación de síntomas de micción (VSS), p<0,001), y la intensidad de la expresión de il-6 se correlacionó estadísticamente con el grado de inflamación (p<0,001). La expresión de il-6 en el tejido prostático fue estadísticamente significativa con IPSS (p=0,018) y SSS (p=0,012). Conclusiones: La expresión de il-6 en el tejido prostático está relacionada con el almacenamiento de IPSS, lo que sugiere que la inflamación crónica puede estar involucrada en el almacenamiento de LUTS. (AU)

Safety and efficacy of Rezum™ in erectile dysfunction patients with and without an inflatable penile prosthesis[[es]]Seguridad y eficacia del sistema Rezum® en pacientes con disfunción eréctil con y sin prótesis de pene inflable.

PURPOSE: This study evaluates the safety and efficacy of Rezum™ in erectile dysfunction (ED) patients with and without an inflatable penile prosthesis (IPP). MATERIALS AND METHODS: This was a retrospective review of ED patients who underwent Rezum™ by a single surgeon over 12 months. Patient age, presence of IPP, number of benign prostatic hyperplasia medications, International Prostate Symptom Score (IPSS), IPSS Quality of Life Index (QOL), uroflowmetry maximum flow rate (Qmax), and uroflowmetry average flow rate (Qavg) before and after Rezum™ were obtained. Independent two-sample T-tests were used to compare preoperative and postoperative characteristics between patients with and without an IPP. Linear regression was performed to identify factors associated with postoperative Qmax or Qavg. RESULTS: A total of 17 patients with ED who underwent Rezum™ were identified, including 11 patients with an IPP. The median follow-up after Rezum™ was 65 days. There were no significant differences in baseline demographics and clinical characteristics between patients with and without an IPP. Postoperative Qmax (10.9 mL/s vs 9.8 mL/s, p = 0.04) and Qavg (7.5 mL/s vs 6.0 mL/s, p = 0.03) were significantly higher in patients with an IPP compared to patients without an IPP. There were no factors associated with postoperative Qmax or Qavg on linear regression. Two patients without an IPP went into urinary retention, while no complications occurred in IPP patients. CONCLUSION: Rezum™ is a safe and effective procedure to perform in ED patients, particularly those with an IPP. IPP patients may experience greater increase in uroflowmetry rate compared to ED patients without an IPP.

Seguridad y eficacia del sistema Rezum en pacientes con disfunción eréctil con y sin prótesis de pene inflable / Safety and efficacy of Rezum in erectile dysfunction patients with and without an inflatable penile prosthesis

Objetivo Este estudio evalúa la seguridad y la eficacia del sistema Rezūm® en los pacientes con disfunción eréctil (DE) con y sin prótesis peneana inflable (PPI). Materiales y métodos Se trata de una revisión retrospectiva de los pacientes con DE tratados con Rezūm® por un único cirujano durante 12 meses. De cada paciente se obtuvo la edad, la presencia de PPI, el número de medicamentos para la hiperplasia prostática benigna, la puntuación internacional de síntomas prostáticos (IPSS), el índice de calidad de vida (QOL) de la IPSS, la tasa de flujo máximo (Qmáx) en la uroflujometría y la tasa de flujo promedio (Qavg) en la uroflujometría antes y después del tratamiento con Rezūm®. Se utilizaron pruebas T para 2 muestras independientes con objeto de comparar las características preoperatorias y postoperatorias entre los pacientes con y sin PPI. Se realizó una regresión lineal para identificar los factores asociados con el Qmáx o Qavg postoperatorio. Resultados Se identificaron un total de 17 pacientes con DE sometidos al sistema Rezūm®, incluyendo 11 pacientes con una PPI. La mediana de seguimiento tras el tratamiento con Rezūm® fue de 65 días. No hubo diferencias significativas en cuanto a los datos demográficos y las características clínicas basales entre los pacientes con y sin PPI. El Qmáx postoperatorio (10,9 frente a 9,8ml/s; p=0,04) y el Qavg (7,5 frente a 6,0ml/s; p=0,03) fueron significativamente mayores en los pacientes con PPI en comparación con los pacientes sin PPI. No hubo factores asociados con el Qmáx o el Qavg postoperatorio en la regresión lineal. Dos pacientes sin PPI resultaron en retención urinaria, mientras que en los pacientes con PPI no se produjeron complicaciones. Conclusión Rezūm® es un procedimiento seguro y eficaz para realizar en pacientes con DE, especialmente en aquellos con una PPI. Los pacientes con PPI pueden experimentar un incremento mayor en los parámetros de uroflujometría en comparación con los pacientes con DE sin PPI (AU)

Purpose This study evaluates the safety and efficacy of Rezūm™ in erectile dysfunction (ED) patients with and without an inflatable penile prosthesis (IPP). Materials and methods This was a retrospective review of ED patients who underwent Rezūm™ by a single surgeon over 12 months. Patient age, presence of IPP, number of benign prostatic hyperplasia medications, International Prostate Symptom Score (IPSS), IPSS Quality of Life Index (QOL), uroflowmetry maximum flow rate (Qmáx), and uroflowmetry average flow rate (Qavg) before and after Rezūm™ were obtained. Independent two-sample T-tests were used to compare preoperative and postoperative characteristics between patients with and without an IPP. Linear regression was performed to identify factors associated with postoperative Qmáx or Qavg. Results A total of 17 patients with ED who underwent Rezūm™ were identified, including 11 patients with an IPP. The median follow-up after Rezūm™ was 65 days. There were no significant differences in baseline demographics and clinical characteristics between patients with and without an IPP. Postoperative Qmáx (10.9ml/s vs. 9.8ml/s, P=.04) and Qavg (7.5ml/s vs. 6.0ml/s, P=.03) were significantly higher in patients with an IPP compared to patients without an IPP. There were no factors associated with postoperative Qmáx or Qavg on linear regression. Two patients without an IPP went into urinary retention, while no complications occurred in IPP patients. Conclusion Rezūm™ is a safe and effective procedure to perform in ED patients, particularly those with an IPP. IPP patients may experience greater increase in uroflowmetry rate compared to ED patients without an IPP (AU)

Association between interleukin-6 and lower urinary tract symptoms of benign prostatic hyperplasia.

OBJECTIVE: To evaluate the association between IL-6 in prostatic tissue/blood sample and BPH-LUTS, so as to preliminarily discover an indicator of inflammation that could show the severity of LUTS. PATIENTS AND METHODS: The prostatic tissues and blood samples were collected from 56 patients who underwent transurethral plasmakinetic resection of the prostate (TUPKRP). The association between IL-6 detected on prostatic tissues/blood sample and LUTS parameters, including international prostate symptom score (IPSS), peak flow rate (Qmax) and urodynamic parameters were analyzed with SPSS version 18.0, and p-value <0.05 was chosen as the criterion for statistical significance. RESULTS: The TPSA and prostate volume (PV) were found to be higher in the inflammation group (p=0.021, 0.036). There was a positive association between prostate tissue inflammation and LUTS ([IPSS, storage symptoms score (SSS), voiding symptoms score (VSS), p<0.05], [Qmax, p=0.025], [obstruction, p=0.027] and [AUR, p=0.018]). The level of serum IL-6 was significantly higher in inflammatory group (p=0.008). However, no differences were observed in different degrees of inflammation (p=0.393). The level of IL-6 in prostatic tissue significantly increased with the degree of inflammation (p<0.001), and the intensity of IL-6 expression was statistically correlative with the degree of inflammation (p<0.001). The IL-6 expression in prostatic tissue was statistically relevant with IPSS (p=0.018) and SSS (p=0.012). CONCLUSION: IL-6 expression in prostatic tissue is associated with storage IPSS, suggesting chronic inflammation might contribute to storage LUTS.

Fitoterapia para los síntomas del tracto urinario inferior en el varón: ¿qué ocurre después? Diez años de investigación / Phytotherapy for male luts: What happens then? 10-year research

Introducción y objetivos Nuestro objetivo es evaluar los resultados de la fitoterapia a largo plazo, centrándonos en el intervalo entre la fitoterapia y los tratamientos farmacológicos y los factores de riesgo que predisponen a dicho cambio en un seguimiento de 10 años. Material y métodos Se revisaron retrospectivamente los datos de los pacientes varones que tomaban fitoterapia para los síntomas del tracto urinario inferior (STUI) de leves a moderados entre enero y diciembre de 2010, a partir de una base de datos mantenida prospectivamente. Se realizó un seguimiento de los pacientes durante 10 años mediante consultas médicas presenciales y telefónicas. Resultados Ciento dos pacientes se sometieron al menos a un ciclo de fitoterapia para los STUI. Veinte (19,6%) pacientes resolvieron sus síntomas tras un ciclo fitoterápico y abandonaron el tratamiento, 27 (26,4%) continuaron con la fitoterapia y 52 (51%) cambiaron a bloqueadores alfa y/o inhibidores de la 5a-reductasa tras un intervalo medio de 24 meses. El motivo del cambio de tratamiento fue la sintomatología (n=45) o la progresión clínica (aumento del volumen residual n=15; retención urinaria, n=5). Los pacientes que cambiaron a fármacos sintéticos tenían una mediana de edad más alta (60 frente a 49), mayor volumen prostático (40 frente a 26cc) y antígeno prostático específico (1,9 frente a 0,9ng/ml), volumen residual más elevado (40 frente a 0cc) y una tasa de flujo máximo (Qmáx) más baja (12 frente a 15ml/s) en el momento de la presentación. Conclusiones El 46% de los pacientes con STUI leves o moderados sometidos a fitoterapia estarán libres de tratamiento o seguirán con la fitoterapia a los 10 años de la presentación de la enfermedad. Los pacientes de mayor edad, con próstatas más grandes, con volumen residual y antígeno protático específico más alto, deben ser informados sobre un mayor riesgo de progresión sintomática o clínica (AU)

Introduction and objectives Our objective is to assess the long-term results of phytotherapy, focusing on the interval between phytotherapy and pharmacological treatment and the predisposing risk factors to such switch on a 10-year follow-up. Material and methods The data of patients taking phytotherapy for mild to moderate male lower urinary tract symptoms (LUTS) from January to December 2010 were retrospectively reviewed from a prospectively maintained database. Patients were followed for 10 years through medical visits and telephone consultations. Results 102 patients underwent at least one cycle of phytotherapy for LUTS. Twenty (19.6%) patients resolved their symptoms after one phytotherapy cycle and stopped any treatment, 27 (26.4%) continued phytotherapy, and 52 (51%) switched to alpha-blockers and/or 5a-reductase inhibitors after a median interval of 24 months. The reasons for treatment switch were symptoms (n=45) or clinical progression (increased residual volume n=15; urinary retention, n=5). Patients switching to synthetic drugs had median higher age (60 vs 49), prostate volume (40 vs 26cc), prostate specific antigen (PSA) (1.9 vs 0.9ng/ml), residual volume (40 vs 0cc), and a lower maximum flow rate (Qmax) (12 vs 15ml/sec) at presentation. Conclusions 46% patients with mild to moderate LUTS undergoing phytotherapy will be either free of treatment or still on phytotherapy at 10 years from disease presentation. Older patients with larger prostates, increased residual volume and PSA, should be informed regarding their higher risk of symptomatic or clinical progression: the risk of a treatment switch to alpha-blockers or 5a-reductase inhibitors becomes an actual fact after an average span of 2 years (AU)

Phytotherapy for male luts: What happens then? 10-year research.

INTRODUCTION AND OBJECTIVES: Our objective is to assess the long-term results of phytotherapy, focusing on the interval between phytotherapy and pharmacological treatment and the predisposing risk factors to such switch on a 10-year follow-up. MATERIAL AND METHODS: The data of patients taking phytotherapy for mild to moderate male lower urinary tract symptoms (LUTS) from January to December 2010 were retrospectively reviewed from a prospectively maintained database. Patients were followed for 10 years through medical visits and telephone consultations. RESULTS: 102 patients underwent at least one cycle of phytotherapy for LUTS. Twenty (19.6%) patients resolved their symptoms after one phytotherapy cycle and stopped any treatment, 27 (26.4%) continued phytotherapy, and 52 (51%) switched to alpha-blockers and/or 5a-reductase inhibitors after a median interval of 24 months. The reasons for treatment switch were symptoms (n = 45) or clinical progression (increased residual volume n = 15; urinary retention, n = 5). Patients switching to synthetic drugs had median higher age (60 vs 49), prostate volume (40 vs 26 cc), prostate specific antigen (PSA) (1.9 vs 0.9 ng/ml), residual volume (40 vs 0 cc), and a lower maximum flow rate (Qmax) (12 vs 15 ml/s) at presentation. CONCLUSIONS: 46% patients with mild to moderate LUTS undergoing phytotherapy will be either free of treatment or still on phytotherapy at 10 years from disease presentation. Older patients with larger prostates, increased residual volume and PSA, should be informed regarding their higher risk of symptomatic or clinical progression: the risk of a treatment switch to alpha-blockers or 5a-reductase inhibitors becomes an actual fact after an average span of 2 years.

Efeito da prática regular do exercício físico sobre a concentração sérica do antígeno prostático específico / Effect of regular physical exercise on serum prostate-specific antigen concentration / Efecto de la práctica de ejercicio físico regular sobre la concentración sérica de antígeno específico prostático

Introdução: O exercício físico vem sendo discutido pela comunidade científica como uma importante estratégia não farmacológica na prevenção de doenças, principalmente para a redução do risco e desenvolvimento de doenças crônicas, como diabetes, obesidade, cânceres, entre outras. Objetivo: Observar a influência do efeito da atividade regular do exercício físico em pessoas vivenciando o processo de envelhecimento por meio da dosagem sérica de PSA, buscando correlacioná-la a fatores de risco para a hiperplasia prostática benigna. Material e Método: Estudo descritivo realizado com homens praticantes e não praticantes de atividade física regular, com faixa etária ≥ 50 anos, os quais foram submetidos à quantificação de PSA sérico, pelo sistema de detecção baseado na utilização de imunotubos com anticorpos policlonais anti-PSA imobilizados na superfície e, aplicação de questionário sobre a faixa etária e fatores de risco para a doença. Resultados: Pela média dos valores de PSA entre o grupo de praticantes de exercício físico regular e não praticantes, não foi possível observar influência do exercício físico sobre a quantificação de PSA (p= 0,7414). A prática regular de atividade física não mostrou efeito significativo sobre os resultados de PSA encontrados na população estudada, de maneira geral. Porém, quando foram avaliados apenas os indivíduos que apresentaram média de PSA acima dos valores de referência (PSA > 2,5 ng/mL para indivíduos até 60 anos e PSA > 4,0 ng/mL para indivíduos acima de 60 anos) se observou que a prática regular de atividade pode auxiliar na diminuição da quantificação do PSA. Conclusão: Exercícios físicos realizados regularmente podem atuar de maneira benéfica nas doenças relacionadas à próstata.(AU)

Introduction: Physical exercise has been discussed by the scientific community as an important non-pharmacological strategy in disease prevention, mainly for the reduction of the risk and development of chronic diseases, such as diabetes, obesity, cancers, among others. Objective: To observe the influence of the effect of regular physical exercise on people experiencing the aging process by measuring serum PSA, seeking to correlate it with risk factors for benign prostatic hyperplasia. Material and Method: Descriptive study carried out with men who practice and who do not practice regular physical activity, aged ≥ 50 years, who underwent quantification of serum PSA, by the detection system based on the use of immunotubes with polyclonal anti-PSA antibodies immobilized on the surface and, application of a questionnaire about the age group and risk factors for the disease. Results: By the mean of PSA values between the group of practitioners of regular physical exercise and nonpractitioners, it was not possible to observe the influence of physical exercise on the quantification of PSA (p= 0.7414). The regular practice of physical activity showed no significant effect on the PSA results found in the population studied, in general. However, when only individuals with a mean PSA above the reference values were evaluated (PSA > 2.5 ng/mL for individuals up to 60 years of age and PSA > 4.0 ng/mL for individuals over 60 years of age), it was observed that the regular practice of activity can help in the reduction of the quantification of the PSA. Conclusion: Physical exercises performed regularly can have a beneficial effect on prostate-related diseases.(AU)

Introducción: El ejercicio físico ha sido discutido por la comunidad científica como una importante estrategia no farmacológica en la prevención de enfermedades, principalmente para la reducción del riesgo y desarrollo de enfermedades crónicas, como diabetes, obesidad, cáncer, entre otras. Objetivo: Observar la influencia del efecto del ejercicio físico regular en personas en proceso de envejecimiento mediante la medición del PSA sérico, buscando correlacionarlo con factores de riesgo para hiperplasia prostática benigna. Material y Método: Estudio descriptivo realizado con hombres practicantes y no practicantes de actividad física regular, con edad ≥ 50 años, a quienes se les realizó cuantificación de PSA sérico, mediante el sistema de detección basado en el uso de inmunotubos con anticuerpos policlonales anti-PSA inmovilizados. en la superficie y, aplicación de un cuestionario sobre el grupo de edad y factores de riesgo para la enfermedad. Resultados: Por la media de los valores de PSA entre el grupo de practicantes de ejercicio físico regular y no practicantes, no fue posible observar la influencia del ejercicio físico en la cuantificación del PSA (p= 0,7414). La práctica regular de actividad física no mostró efecto significativo en los resultados de PSA encontrados en la población estudiada, en general. Sin embargo, cuando solo se evaluaron individuos con un PSA medio por encima de los valores de referencia (PSA > 2,5 ng/mL para personas de hasta 60 años y PSA > 4,0 ng/mL para personas mayores de 60 años), fue observó que la práctica regular de actividad puede ayudar en la...(AU)

Risk factors for perioperative complications in transurethral prostate resection in patients at a Colombian institution. / Factores de riesgo para complicaciones perioperatorias en la resección transuretral de próstata en pacientes de una institución de Colombia.

OBJECTIVE: Determining the complications rate and the risk factors associated with early operative and postoperative complications with a bipolar transurethral resection of the prostate at a complex care institution in Colombia. MATERIALS AND METHODS: A mixed cohort study was conducted involving 340 patients diagnosed with benign prostatic hyperplasia who were taken to bipolar transurethral resection of the prostate between 2012 and 2019. Data based on the baseline and perioperative characteristics were collected, and the rate of complications determined up to 30 postoperative days. RESULTS: A total of 67 patients (19.45%) presented perioperative complications of which 17 (25.37%) were previously hospitalized. According to the Clavien Dindo classification, 14.79% were grade I - II: secondary hematuria was the most reported complication and was present in 18 patients (5.22%), followed by complicated urinary tract infections in 16 (4.64%) and dysfunction of the ureterovesical catheter in 6 (1.76%). The risk factors found were surgery during hospitalization (RR:2.23, 95% CI: 1.14 - 4.39), INR (RR: 7.59, IC95%:4.63 - 12.44), duration in days of cysto/irrigation (RR:1.32, CI95%: 1.22 - 1.42) and urethral catheter use (RR: 1.04, CI95%: 1.02 - 1.05). CONCLUSIONS: In this study, the complication rate after bipolar transurethral resection of the prostate was less than 20%. The most frequent complications were grade Iand II according to the Clavien Dindo classification. The risk factors that were found are modifiable, which could reduce postoperative morbidity.

OBJETIVO: Determinar la tasa de complicaciones y los factores de riesgo para complicaciones perioperatorias tempranas de la Resección Transuretral de Próstata con bipolar (RTUP-B) en una institución prestadora de servicios de salud de Colombia. MATERIALES Y MÉTODOS: Se realizó un estudio de cohortes mixta en el cual se incluyeron 340 pacientes con diagnóstico de Hiperplasia Prostática Benigna (HPB) que fueron llevados a RTUP-B entre el año 2012y 2019. Se recolectaron datos sobre las características basales y perioperatorias y se determinó la tasa de complicaciones hasta los 30 días postoperatorio. RESULTADOS: 67 pacientes (19,45%) presentaron complicaciones perioperatorias de las cuales 17 (25,37%) fueron intrahospitalarias. Según la clasificación Clavien Dindo el 14,79% fueron complicaciones grado I y II: la hematuria secundaria fue la complicación más reportada en (5,22%), seguida de infecciones del tracto urinario (4,64%) y disfunción de la sonda uretrovesical (1,76%). Los factores de riesgo fueron: estancia hospitalaria previo a la cirugía por cualquier causa (RR:2,23, IC95%: 1,14 ­ 4,39), aumento del valor del INR por unidad (RR: 7,59, IC95%: 4,63 ­ 12,44) y cada día adicional de irrigación vesical (RR: 1,32, IC95%:1,22 ­ 1,42) y sonda vesical (RR: 1,04, IC95%: 1,02­ 1,05). CONCLUSIONES: En este estudio, la tasa de complicaciones después de la RTUP con bipolar fue de meno rdel 20%, siendo las complicaciones grados I y II las más frecuentes. Los factores de riesgo encontrados son modificables lo que podría reducir la morbilidad postoperatoria.

Factores de riesgo para complicaciones perioperatorias en la resección transuretral de próstata en pacientes de una institución de colombia / Risk factors for perioperative complications in transurethral resection of the prostate in patients from a Colombian institution

Objetivo: Determinar la tasa de complicaciones y los factores de riesgo para complicacionesperioperatorias tempranas de la Resección Transuretralde Próstata con bipolar (RTUP-B) en una institución prestadora de servicios de salud de Colombia. Materiales y métodos: Se realizó un estudio decohortes mixta en el cual se incluyeron 340 pacientes con diagnóstico de Hiperplasia Prostática Benigna(HPB) que fueron llevados a RTUP-B entre el año 2012y 2019. Se recolectaron datos sobre las característicasbasales y perioperatorias y se determinó la tasa de complicaciones hasta los 30 días postoperatorio. Resultados: 67 pacientes (19,45%) presentaron complicaciones perioperatorias de las cuales 17 (25,37%)fueron intrahospitalarias. Según la clasificación ClavienDindo el 14,79% fueron complicaciones grado I y II:la hematuria secundaria fue la complicación más reportada en (5,22%), seguida de infecciones del tractourinario (4,64%) y disfunción de la sonda uretrovesical(1,76%). Los factores de riesgo fueron: estancia hospitalaria previo a la cirugía por cualquier causa (RR:2,23, IC95%: 1,14 – 4,39), aumento del valor del INRpor unidad (RR: 7,59, IC95%: 4,63 – 12,44) y cadadía adicional de irrigación vesical (RR: 1,32, IC95%:1,22 – 1,42) y sonda vesical (RR: 1,04, IC95%: 1,02– 1,05). Conclusiones: En este estudio, la tasa de complicaciones después de la RTUP con bipolar fue de menordel 20%, siendo las complicaciones grados I y II lasmás frecuentes. Los factores de riesgo encontrados sonmodificables lo que podría reducir la morbilidad postoperatoria.(AU)

Objetive: Determining the complications rate and the risk factors associated with early operative and postoperative complications with a bipolartransurethral resection of the prostate at a complex careinstitution in Colombia. Material and methods: A mixed cohort study wasconducted involving 340 patients diagnosed with benign prostatic hyperplasia who were taken to bipolartransurethral resection of the prostate between 2012and 2019. Data based on the baseline and perioperative characteristics were collected, and the rate ofcomplications determined up to 30 postoperative days. Results: A total of 67 patients (19.45%) presentedperioperative complications of which 17 (25.37%)were previously hospitalized. According to the ClavienDindo classification, 14.79% were grade I – II: secondary hematuria was the most reported complication andwas present in 18 patients (5.22%), followed by complicated urinary tract infections in 16 (4.64%) and dysfunction of the ureterovesical catheter in 6 (1.76%). The riskfactors found were surgery during hospitalization (RR:2.23, 95% CI: 1.14 – 4.39), INR (RR: 7.59, IC95%:4.63 – 12.44), duration in days of cysto/irrigation (RR:1.32, CI95%: 1.22 – 1.42) and urethral catheter use(RR: 1.04, CI95%: 1.02 – 1.05). Conclusions: In this study, the complication rate after bipolar transurethral resection of the prostate was lessthan 20%. The most frequent complications were grade Iand II according to the Clavien Dindo classification. Therisk factors that were found are modifiable, which couldreduce postoperative morbidity.(AU)

Embolización prostática como tratamiento para pacientes con hiperplasia benigna de próstata portadores de sonda vesical permanente no tributarios a cirugía desobstructiva / Prostatic artery embolization treatment for patients with benign prostatic hyperplasia who are permanent urinary catheter users ineligible for de-obstructive surgery

Introducción: La hiperplasia benigna de próstata se considera la causa más común de los síntomas del tracto urinario inferior. El sondaje vesical es el tratamiento urgente en pacientes con retención urinaria y la cirugía el de aquellos refractarios al tratamiento médico. Existe un grupo de personas con comorbilidades importantes no tributarias a cirugía. La embolización arterial prostática (EAP) podría presentarse como una alternativa segura y eficaz para conseguir el vaciamiento vesical y la micción espontánea, evitando así el sondaje vesical permanente en pacientes con comorbilidades importantes que contraindiquen la cirugía. En este estudio retrospectivo, evaluamos la eficacia de la EAP en pacientes portadores de sonda vesical permanente no tributarios de tratamiento quirúrgico.Material y métodosEstudio retrospectivo de 26 pacientes portadores de sonda vesical permanente a los que se les realizó una embolización prostática. Se revisaron los datos demográficos y clínicos (edad, uso de anticoagulación, volumen prostático, tiempo de ingreso, embolización unilateral o bilateral), la evaluación del índice de comorbilidad de Charlson y la clasificación de Clavien-Dindo para las complicaciones del procedimiento. Se analizó el éxito de la retirada de la sonda vesical permanente al mes del procedimiento.ResultadosUn total de 26 pacientes fueron incluidos en la revisión. La mediana de edad fue de 85 años, con un volumen prostático mediano de 90mL. El 88,5% de los sujetos puntuó más de 7 en la escala de comorbilidad de Charlson. Un único paciente presentó una complicación Clavien-Dindo III. De los 26 sujetos, 17 (65,4%) tuvieron una micción espontánea y un residuo posmiccional inferior a 100mL al mes del procedimiento. En total, se logró retirar la sonda vesical en 19 de los 26 sujetos (73,1%). (AU)

Introduction: Benign prostatic hyperplasia is considered the most frequent cause of lower urinary tract symptoms. Urinary catheterization is the emergency treatment for patients with urinary retention and surgery is indicated in patients refractory to medical treatment. There is a group of people with important comorbidities that make them ineligible for surgery. Prostatic arterial embolization (PAE) could be presented as a safe and effective alternative to achieve bladder emptying and spontaneous urination, thus avoiding permanent urinary catheterization in patients with significant comorbidities that represent a contraindication for surgery. In this retrospective study, we evaluated the efficacy of PAE in patients with permanent urinary catheterization who are ineligible for surgical treatment.Material and methodsRetrospective study of 26 patients with permanent urinary catheter who underwent prostatic embolization. Demographic and clinical data (age, use of anticoagulation, prostate volume, length of hospital stay, unilateral or bilateral embolization), Charlson comorbidity index evaluation and Clavien-Dindo classification for procedural complications were reviewed. Successful removal of permanent urinary catheter was analyzed at one month after the procedure.ResultsA total of 26 patients were included in the review. The median age was 85 years with a median prostate volume of 90mL. A Charlson comorbidity score above 7 was obtained in 88.5% of the subjects. Only one patient had one Clavien-Dindo III complication. Of the 26 subjects, 17 (65.4%) had spontaneous micturition and a postvoid residual lower than 100mL at one month post procedure. Overall, catheter removal was achieved in 19 out of 26 subjects (73.1%). (AU)

Prostatic artery embolization treatment for patients with benign prostatic hyperplasia who are permanent urinary catheter users ineligible for de-obstructive surgery.

INTRODUCTION: Benign prostatic hyperplasia is considered the most frequent cause of lower urinary tract symptoms. Urinary catheterization is the emergency treatment for patients with urinary retention and surgery is indicated in patients refractory to medical treatment. There is a group of people with important comorbidities that make them ineligible for surgery. Prostatic arterial embolization (PAE) could be presented as a safe and effective alternative to achieve bladder emptying and spontaneous urination, thus avoiding permanent urinary catheterization in patients with significant comorbidities that represent a contraindication for surgery. In this retrospective study, we evaluated the efficacy of PAE in patients with permanent urinary catheterization who are ineligible for surgical treatment. MATERIAL AND METHODS: Retrospective study of 26 patients with permanent urinary catheter who underwent prostatic embolization. Demographic and clinical data (age, use of anticoagulation, prostate volume, length of hospital stay, unilateral or bilateral embolization), Charlson comorbidity index evaluation and Clavien-Dindo classification for procedural complications were reviewed. Successful removal of permanent urinary catheter was analyzed at one month after the procedure. RESULTS: A total of 26 patients were included in the review. The median age was 85 years with a median prostate volume of 90 mL. A Charlson comorbidity score above 7 was obtained in 88.5% of the subjects. Only one patient had one Clavien-Dindo III complication. Of the 26 subjects, 17 (65.4%) had spontaneous micturition and a postvoid residual lower than 100 mL at one month post procedure. Overall, catheter removal was achieved in 19 out of 26 subjects (73.1%). CONCLUSION: PAE is a safe and effective treatment for patients with permanent urinary catheterization who are ineligible for surgical treatment.

Vulnerabilidade de pacientes com hiperplasia prostática tratados com dutasterida e finasterida / Vulnerability of patients with prostatic hyperplasia treated with dutasteride and finasteride / Vulnerabilidad de pacientes con hiperplasia prostática tratados con dutasterida y finasterida

Resumo A hiperplasia prostática benigna é uma patologia cuja incidência vem crescendo muito nos últimos anos, em todo o Brasil. A doença está correlacionada a fatores hormonais, e o tratamento farmacológico pode gerar efeitos adversos nos pacientes. O objetivo deste estudo é avaliar fatores socioeconômicos e socioculturais que interferem na cura ou reduzem a qualidade de vida. Analisamos dados de plataformas do Governo Federal entre janeiro de 2009 a setembro de 2019, observando fatores como etnia, nível de escolaridade e situação econômica dos pacientes. Em todas as regiões do Brasil esses fatores se mostraram importantes, pois podem afetar diretamente a incidência da doença e a adesão e continuidade do tratamento.

Summary Benign prostatic hyperplasia is a pathology whose incidence has been increasing in recent years throughout Brazil. The disease is correlated with hormonal factors, and pharmacological treatment can have adverse effects on patients. This study assesses the socioeconomic and socio-cultural factors that interfere with healing or reduce quality of life. We analyzed data from Federal Government platforms between January 2009 and September 2019, looking at factors such as ethnicity, education level and economic status of patients. In all regions of Brazil, these factors proved to be important, as they can directly affect the incidence of the disease and adherence and continuity of treatment.

Resumen La hiperplasia prostática benigna es una patología cuya incidencia ha ido creciendo mucho en los últimos años, en todo Brasil. La enfermedad se correlaciona con factores hormonales, y el tratamiento farmacológico puede generar efectos adversos en los pacientes. El objetivo de este estudio es evaluar factores socioeconómicos y socioculturales que interfieren con la curación o reducen la calidad de vida. Analizamos datos de plataformas del Gobierno Federal entre enero de 2009 y septiembre de 2019, observando factores como el origen étnico, el nivel educativo y la situación económica de los pacientes. En todas las regiones de Brasil, estos factores demostraron ser importantes, ya que pueden afectar directamente la incidencia de la enfermedad y la adherencia y continuidad del tratamiento.

Quality of life and erectile dysfunction in patients with benign prostatic hyperplasia.

ANTECEDENTES: La patología de la próstata más frecuente es la hiperplasia prostática benigna. A los 50 años, el 50% de los hombres son diagnosticados y a los 80 años aumenta hasta al 90%. La prevalencia de disfunción eréctil en conjunto con hiperplasia prostática benigna es del 5.2-40%, y los pacientes con hiperplasia prostática benigna es 1.33-6.24 veces más frecuente que tengan disfunción eréctil que aquellos sin hiperplasia prostática benigna. Ambas afecciones repercuten en la calidad de vida. OBJETIVO: Identificar la calidad de vida y el grado de disfunción eréctil en pacientes con hiperplasia prostática benigna. MÉTODO: Estudio transversal, descriptivo, en pacientes con crecimiento prostático benigno a los cuales se les aplicaron dos cuestionarios: SF-12 para calidad de vida e Índice Internacional de Función Eréctil versión 5 para disfunción eréctil. RESULTADOS: Fueron 101 pacientes, edad media de 66.5 ± 8.5 años, promedio físico de 38.68, promedio mental de 43.35, 14 de ellos sin disfunción eréctil y 38 con disfunción eréctil leve, 33 leve a moderada, 15 moderada y 1 grave. CONCLUSIONES: Los pacientes con hiperplasia prostática benigna tienen una salud física mala y una salud mental buena. El 70.3% de los pacientes muestran grado leve o leve-moderado de disfunción eréctil. BACKGROUND: The most frequent prostatic pathology is benign prostatic hyperplasia. By the age of 50, 50% are diagnosed with it and by the age of 80, it increases to 90%. The erectile dysfunction prevalence along benign prostatic hyperplasia is 5.2%-40%. Patients with benign prostatic hyperplasia are 1.33-6.24 times more likely to have erectile dysfunction tan without benign prostatic hyperplasia. OBJECTIVE: To identify quality of life and to grade erectile dysfunction in patients with benign prostatic hyperplasia. METHOD: A transversal, descriptive study was conducted in patients with benign prostatic hyperplasia. Two questionnaires were applied: SF-12 for quality of life and IIEF-5 for erectile dysfunction. RESULTS: 101 patients, mean age 66.5 ± 8.5 years, mean physical aspect 38.68, mean mental aspect 43.35, 14 without erectile dysfunction, 38 mild grade, 33 mild to moderate, 15 moderate and 1 severe. CONCLUSIONS: Benign prostatic hyperplasia patients have poor physical health and good mental health. 70.3% of patients have a grade of erectile dysfunction between mild and mild-moderate.

Hiperplasia prostática benigna y síntomas del tracto urinario inferior / Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms

Introducción: La hiperplasia prostática benigna constituye un problema de primer nivel de atención de salud por su alta prevalencia en los hombres. Objetivo: Identificar la presencia de síntomas del tracto urinario inferior relacionados a la hiperplasia prostática benigna y su repercusión en la calidad de vida de hombres de 50 o más años de edad, sin diagnóstico previo de hiperplasia prostática benigna, que asistieron al centro de salud de la parroquia Javier Loyola. Métodos: Estudio descriptivo transversal entre noviembre del 2018 y enero 2019, que incluyó al total pacientes (106), que asistieron al centro de salud de la parroquia Javier Loyola y que aceptaron completar la Escala internacional de síntomas prostáticos. Los datos fueron analizados por medio de la estadística descriptiva y el test de χ2. Resultados: El 35,3 por ciento de investigados pertenecieron al grupo etario de 40 a 50 años, la presencia de síntomas del tracto urinario inferior leves (38,8 por ciento), moderados (39,7 por ciento) y severos (21,5 por ciento). Prevalecieron en porcentaje de participantes los desocupados (22,4 por ciento), los albañiles (23,3 por ciento), los hipertensos (26,7 por ciento), diabéticos (17,2 por ciento) y obesos (14,7 por ciento). La severidad de los síntomas del tracto urinario inferior no se asoció significativamente al tipo de ocupación. El 61,2 por ciento de pacientes presentaban síntomas del tracto urinario inferior moderados o severos y un 56,8 por ciento percibieron que su calidad de vida se veía afectada de alguna manera por los síntomas del tracto urinario inferior. Conclusiones: Preocupa el alto porcentaje de participantes con síntomas del tracto urinario inferior moderados/severos sin un diagnóstico previo de hiperplasia prostática benigna y con percepción de que su calidad de vida se ve afectada. La severidad de los síntomas del tracto urinario inferior incrementó con la edad y no a otros factores, excepto la ocupación(AU)

Introduction: Benign prostatic hyperplasia constitutes a first-level healthcare concern, due to its high prevalence among men. Objective: To identify the presence of lower urinary tract symptoms related to benign prostatic hyperplasia and its impact on the quality of life of men aged 50 years or older, without a previous diagnosis of benign prostatic hyperplasia, who attended the health center of Javier Loyola Parish. Methods: Cross-sectional descriptive study carried out between November 2018 and January 2019, which included all the patients (106) who attended the health center of Javier Loyola Parish and agreed to complete the International Prostate Symptom Scale. The data were analyzed using descriptive statistics and the chi-square test. Results: 35.3 percent of the participants belonged to the age group from 40 to 50 years. The presence was observed of mild (38.8 percent), moderate (39.7 percent) and severe (21.5 percent) lower urinary tract symptoms. There was a prevalence of unemployed (22.4 percent), bricklayers (23.3 percent), hypertensive (26.7 percent), diabetic (17.2 percent) and obese (14.7 percent) participants. The severity of the lower urinary tract symptoms was not significantly associated with the type of occupation. 61.2 percent of patients had mild or severe lower urinary tract symptoms and 56.8 percent perceived that their quality of life was affected, in some way, by lower urinary tract symptoms. Conclusions: There is concern about the high percentage of participants with mild or severe lower urinary tract symptoms, without a previous diagnosis of benign prostatic hyperplasia, and with some perception that their quality of life is affected is. The severity of lower urinary tract symptoms increased with age but not with other factors, except occupation(AU)

Influencia de la modalidad de respuesta, edad y nivel de educación en el cuestionario internacional de síntomas prostáticos (IPSS) / Influence of the response modality, age and level of education in the international prostate symptoms questionnaire (IPSS)

OBJETIVOS: evaluar la influencia de la modalidad de respuesta (paciente vs. asistido por urólogo) en el cuestionario IPSS (International Prostate Symptom Score) y su relación con la edad y nivel de educación. MATERIALES Y MÉTODOS: Análisis prospectivo de 74 pacientes que acudieron a la consulta de urología por síntomas de Hiperplasia Prostática Benigna (HPB) con o sin tratamiento para su patología y que no hayan completado anteriormente el cuestionario internacional de síntomas prostáticos (IPSS). Los cuestionarios fueron completados en la misma consulta urológica, primero por el paciente y luego con ayuda del urólogo. Se categorizó por edad y nivel de educación. Se evaluó la diferencia entre los puntajes de IPSS obtenidos con la forma autocompletada y con asistencia del urólogo y si esta diferencia estaba relacionada con la edad y con el nivel de educación. Los datos fueron analizados utilizando test no paramétrico para datos apareados de Wilcoxon. RESULTADOS: no se encontró diferencia estadísticamente significativa entre el cuestionario completado por el paciente y el asistido por el urólogo. La media del score total fue de 13,66, y 13,67, respectivamente (p: 0.86). Al analizar los subgrupos, con respecto a la edad y al nivel de educación, tampoco se encontraron diferencias estadísticamente significativas. CONCLUSIÓN: en nuestra población de estudio, el cuestionario IPSS no fue influenciado por la modalidad de administración, tampoco por la edad ni por el nivel de educación.

OBJECTIVES: to evaluate the influence of the response modality (patient vs. urologist-assisted) in the IPSS questionnaire (international prostate symptom score) and its relationship with age and education level. MATERIALS AND METHODS: Prospective analysis of 74 patients who came to the urology clinic for symptoms of Benign Prostatic Hyperplasia (BPH) with or without treatment for their pathology and who have not previously completed the international prostate symptoms questionnaire (IPSS). The questionnaires were completed in the same urological consultation, first by the patient and then with the help of the urologist. It was categorized by age and education level. The difference between the IPSS scores obtained with the self-completed form and with the assistance of the urologist and whether this difference was related to age and level of education was evaluated. The data were analyzed using non-parametric test for paired Wilcoxon data. RESULTS: no statistically significant difference was found between the questionnaire completed by the patient and the one assisted by the urologist. The average of the total score was 13.66, and 13.67, respectively (p: 0.86). When analyzing the subgroups, regarding age and level of education, no statistically significant differences were found. CONCLUSION: In our study population, the IPSS questionnaire was not influenced by the modality of administration, neither by age nor by level of education.

Protective effect of black mulberry (Morus nigra L.) fruit hydroalcoholic extract against testosterone-induced benign prostatic hyperplasia in rats.

BACKGROUND: Finding new agents for prevention and/or treatment of benign prostatic hyperplasia (BPH) especially from natural sources is a demanding field. OBJECTIVES: This study aimed to evaluate the effect of black mulberry (BM) (Morus nigra) fruit hydroalcoholic extract on the establishment of BPH in rats. MATERIALS AND METHODS: Forty-nine adult male rats were randomly assigned into 7 equal groups: I: Sham control (SC), a sham surgery was performed. II: positive control (PC), rats were castrated and received testosterone propionate, at 10mg/kg/day S.C. for BPH induction. III: comparative control (CC), BPH was induced and the rats received finasteride at 5mg/kg/day P.O. IV-VII: (T1-T4): BPH was induced and the rats received BM extract at 25, 50, 100 and 200mg/kg/day P.O. for 4 consecutive weeks. RESULTS: Finasteride and/or BM extract especially at the two higher dosages, significantly affected prostate weight, prostatic index, percent of inhibition, serum and prostatic levels of dihydrotestosterone (DHT), serum prostate-specific antigen (PSA), antioxidant parameters of prostatic tissue as well as histopathological and histomorphometric parameters (epithelial thickness and acinar area) of prostate. CONCLUSIONS: BM extract has protective effects against experimentally-induced BPH in rats with regard to histopathological and biochemical parameters which may be related to its antioxidant as well as DHT reducing properties in prostatic tissue.

The complications of the HoLEP learning curve. A systematic review. / Análisis de las complicaciones en el aprendizaje del HoLEP: revisión sistemática.

BACKGROUND: Holmium laser enucleation of the prostate (HoLEP) could have better outcomes with decreased complication rates if compared to traditional techniques (transurethral resection and open prostatectomy) for the surgical relief of bladder outlet obstruction. Despite this, its use has not been implemented in the urology community, probably due to the high complication rates of the HoLEP learning curve (HoLC). OBJECTIVE: To conduct a systematic review of the complication rates in HoLC and compare these with those of traditional techniques. EVIDENCE ACQUISITION: a systematic literature search was performed in MedLine and Embase using the search terms «HoLEP¼ and «holmium laser enucleation¼. We identified 680 records and selected 15 studies following PRISMA criteria. EVIDENCE SYNTHESIS: 1705 cases in the learning curves of 59 surgeons were analyzed. Most of the studies do not report complications in a standardized way. Intraoperative complication rates are low and usually without long-term impact. Postoperative complication rates are limited and show improvement with practice. The complication rates in the HoLC are similar or lower to those reported by traditional techniques. CONCLUSION: Complication rates in HoLC are not higher than those reported by traditional techniques. HoLEP learning should not be delayed for fear of increasing complications or their severity.

Comparación de los resultados clínicos en pacientes con Hiperplasia prostática benigna con tratamiento inicial Farmacológico, no farmacológico y quirúrgico, atendidos en el Hospital Pablo Arturo Suárez de enero 2014 a diciembre 2016 / Comparison of the clinical results in patients with benign prostatic hyperplasia with initial pharmacological, non-pharmacological and surgical treatment, managed at Pablo Arturo Suárez Hospital from january 2014 to december 2016

Contexto: Al momento existen pocos datos científicos que comparen las tres modalidades de tratamiento en Hiperplasia Prostática Benigna para determinar el mejor resultado clínico, considerando que se trata de una patología cuya incidencia aumenta a medida que aumenta la esperanza de vida poblacional. Objetivo: Comparar los resultados clínicos entre el tratamiento inicial farmacológico, no farmacológico y quirúrgico, basándose en la clínica de prostatismo en pacientes con Hiperplasia Prostática Benigna durante el período de enero 2014 a diciembre 2016. Diseño: Estudio Observacional, tipo Cohorte Retrospectiva. Pacientes y Métodos: Se procedió a dividir a 399 pacientes de acuerdo a la modalidad de tratamiento recibida. Se comparó la disminución del cuadro clínico en la primera consulta postratamiento utilizando una matriz de evaluación de síntomas urinarios elaborada por los autores, basada en la escala IPSS, que estratificó a los pacientes por el grado de severidad de la sintomatología. Se utilizó el software SPSS®. Resultados: Dentro del tratamiento no farmacológico, existió una diferencia de medias de 1,67 (IC 95% 0,49 ­ 2,85, p < 0,05); para el farmacológico fue de 0,21 (IC 95% 0,92 ­ 1,34, p = 0,713) y para el quirúrgico fue de 8,23 (IC 95% 7,19 ­ 9,27, p < 0,05). Se encontraron diferencias significativas entre los tres grupos durante la fase pretratamiento, tras estratificarlos de acuerdo al grado de severidad. Post- intervención, se compararon los resultados clínicos de cada tratamiento hallando que en pacientes con síntomas leves no existieron diferencias significativas (p = 0,087), no así para pacientes con sintomatología moderada y severa en donde se encontró una diferencia estadísticamente significativa. Conclusión: En pacientes con sintomatología urinaria catalogada como moderada y severa dentro de esta muestra, el tratamiento quirúrgico disminuyó la sintomatología urinaria en mayor proporción en comparación con el tratamiento farmacológico y el no farmacológico

Background: Currently there are few scientific data comparing the three therapeutic modalities of Benign Prostatic Hyperplasia to determine the best clinical outcome, considering that it is a pathology whose incidence increases as population life expectancy arise. Objectives: To compare the clinical results between the initial pharmacological, nonpharmacological and surgical treatment, based on clinical signs of prostatism in patients with benign prostatic hyperplasia during the period between January 2014 and December 2016. Study Design: Retrospective Cohort Study. Methods: 399 patients were divided according to the modality of treatment received: nonpharmacological, pharmacological and surgical. The decrease of the symptoms was compared with the first post-treatment consultation by using a matrix of evaluation of urinary symptoms elaborated by the authors, based on SPSS International Score; this tool stratified the patients by the severity of the symptomatology. SPSS® software was used. Results: Within the non-pharmacological treatment, there was a mean difference of 1.67 (95% CI 0.49 - 2.85, p <0.05); for the pharmacological it was 0.21 (95% CI 0.92 - 1.34, p = 0.713) and for the surgical was 8.23 (95% CI 7.19 - 9.27, p <0.05). Significant differences were found between the three groups during the pretreatment phase, after stratifying them according to the degree of severity. Post-intervention, the clinical results of each treatment were compared, finding that in patients with mild symptoms there were no significant differences (p = 0.087), not so for patients with moderate and severe symptoms where a statistically significant difference was found. Conclusion: In patients with urinary symptoms classified as moderate and severe within this sample, surgical treatment decreased urinary symptomatology in greater proportion compared to pharmacological and non-pharmacological treatment

La próstata desde una perspectiva inmunológica / The prostate from an immunological perspective

Los procesos inflamatorios e infecciosos que se desencadenan en la próstata, primordial glándula reproductiva masculina, originan las tres principales enfermedades de este órgano: prostatitis, hiperplasia prostática benigna y cáncer. Para entender la relación que existe entre estas tres patologías y los procesos de infección e inflamación, se realizó una revisión de la literatura científica, a conveniencia, en la base de datos PubMed, empleando los términos próstata, prostatitis, hiperplasia prostática benigna y cáncer de próstata. La literatura revisada resalta la importancia del adecuado funcionamiento del sistema inmune en el tejido prostático para eliminar los microorganismos causantes de infecciones, proceso a través del cual se desencadena la inflamación del tejido. Además, infecciones urinarias ascendentes, que culminan en prostatitis crónica, favorecen el desarrollo de la hiperplasia prostática benigna, agrandamiento y fibrosis de la próstata en hombres adultos, e incluso su progresión a cáncer en individuos genéticamente susceptibles. Por otro lado, las limitaciones en el diagnóstico de las alteraciones prostáticas promueven la inflamación crónica, y el uso indiscriminado de antibióticos de amplio espectro para el tratamiento de la prostatitis, impulsa la diseminación sexual de microorganismos multirresistentes al tratamiento. Las alteraciones prostáticas, en especial la prostatitis, continúan siendo patologías enigmáticas de difícil diagnóstico y tratamiento. El estudio de la próstata, sus alteraciones y su relación con el sistema inmune contribuirán a limitar el uso indiscriminado de antibióticos y a reducir los costos en salud y los efectos sobre la calidad de vida de los individuos afectados

Inflammatory and infectious processes triggered in the prostate, the primary male reproductive gland, originate the three main diseases of this organ: prostatitis, benign prostatic hyperplasia and cancer. To understand the relationship between these three pathologies and inflammatory and infectious processes, a review of the scientific literature was carried out in PubMed database using the terms prostate, prostatitis, benign prostatic hyperplasia and prostate cancer. The revised articles highlight the importance of properly immune system functioning in the prostate tissue to remove the microorganisms that cause infections, a process which also triggers tissue inflammation. In addition, ascending urinary infections, which culminate in chronic prostatitis, favor the development of benign prostatic hyperplasia, enlargement and fibrosis of the prostate in adult men, and even its progression to cancer in genetically susceptible individuals. Furthermore, limitations in the diagnosis of prostatic disorders promote chronic inflammation, and the indiscriminate use of broad spectrum antibiotics for prostatitis treatment leads to sexual dissemination of multidrug-resistant microorganisms. Prostatic disorders, especially prostatitis, continue to be enigmatic pathologies of difficult diagnosis and treatment. The study of the prostate, its disorders and its relationship with the immune system will contribute to limit the indiscriminate use of antibiotics and to reduce health costs and the effects on the quality of life of affected individuals